MAPT and Parkinson disease: Recent studies have suggested that several biomarkers including blood apolipoprotein E ɛ4 (ApoE4) genotype, cerebrospinal fluid (CSF) Aβ1–42 (lower) and tau (higher) have been associated with cognitive impairment in PD in cross sectional studies [13–16].